Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation study of elimusertib (BAY 1895344) in advanced solid tumors and lymphomas
jRCT2080223941Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of elimusertib in Nonhematologic neoplasms, non-Hodgkin lymphoma (NHL), castration-resistant prostate cancer (CRPC) and 8 more (2 arms), sponsored by Bayer. Primary endpoints: Maximum tolerated dose (MTD) of elimusertib, Recommended Phase 2 dose (RP2D) and 1 more. Started Jun 2018; status: completed.
02
Drugs
elimusertib
03
Conditions
Nonhematologic neoplasmsnon-Hodgkin lymphoma (NHL)castration-resistant prostate cancer (CRPC)bronchial carcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080223941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223941.